| Related Articles |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy.
Clin Pharmacol Ther. 2019 Feb 22;:
Authors: Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, Gaedigk A, Klein TE, Caudle KE, McCracken JT, de Leon J, Steven Leeder J
Abstract
Atomoxetine is a non-stimulant medication used to treat attention-deficit/hyperactivity disorder. CYP2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for atomoxetine based on CYP2D6 genotype (updates at www.cpicpgx.org). This article is protected by copyright. All rights reserved.
PMID: 30801677 [PubMed – as supplied by publisher]
via https://www.ncbi.nlm.nih.gov/pubmed/30801677?dopt=Abstract
